Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 -0.0639625585023401 -0.0717628705148207
Stock impact report

Passage Bio Achieves Milestones in Gene Therapy Trials [Yahoo! Finance]

Passage Bio, Inc. (PASG) 
Company Research Source: Yahoo! Finance
therapy trials for FTD-GRN, revealing promising interim data that shows potential as a leading progranulin-raising therapy. With patient enrollment on track and robust preclinical data presented at key scientific conferences, the company is poised to achieve critical milestones, supported by a strong financial position ensuring operations until mid-2026. This progress underscores Passage Bio's commitment to advancing treatments for neurodegenerative diseases. For an in-depth examination of PASG stock, go to TipRanks' Stock Analysis page Shareholder Alert for WM Technology Inc. (NASDAQ:MAPS) Class Action Lawsuit Against Domino's Pizza, Inc. (NYSE:DPZ) 3 Penny Stocks to Watch Now, 11/24/24 Show less Read more
Impact Snapshot
Event Time:
PASG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
PASG alerts

from News Quantified
Opt-in for
PASG alerts

from News Quantified